Target intelligence / Profile preview

Glutamate receptor ionotropic NMDA type subunit 2C (GRIN2C) (GRIN2C)

Target
GRIN2C
Molecular classification
Ion channel, Ligand-gated ion channel, Glutamate receptor, NMDA receptor
01

Overview

The Glutamate receptor ionotropic NMDA type subunit 2C (GRIN2C) is a critical component of the N-methyl-D-aspartate (NMDA) receptor complex, a ligand-gated ion channel essential for excitatory neurotransmission in the mammalian central nervous system (UniProt: Q14957). Unlike other GluN2 subunits, GRIN2C is predominantly expressed in the cerebellum, where it plays a specialized role in motor coordination and synaptic integration (PubMed: 25339738). NMDA receptors containing the 2C subunit exhibit unique biophysical properties, including reduced sensitivity to magnesium blockade and lower single-channel conductance, which allow for distinct signaling profiles during low-frequency stimulation (NCBI Gene: 2905). Dysregulation or mutations in GRIN2C have been linked to various neuropsychiatric and neurological conditions, including schizophrenia, epilepsy, and neurodevelopmental delays (PubMed: 31630015). Pharmacologically, while many NMDA antagonists are non-selective, the 2C subunit is a target for developing subtype-specific modulators aimed at treating cognitive deficits and mood disorders with fewer side effects than broad-spectrum blockers (PubChem: 4054).

Other names
GluN2CNR2CN-methyl D-aspartate receptor subtype 2CNMDAR2CGlutamate [NMDA] receptor subunit epsilon-3
02

Mechanism of action

NMDA receptor subunits form heterotetrameric ion channels. Drugs targeting these receptors act as uncompetitive antagonists (pore blockers), competitive antagonists at the glutamate or glycine binding sites, or allosteric modulators that alter channel gating or affinity (PubMed: 25339738).

03

Biological functions

Synaptic plasticityExcitatory neurotransmissionCalcium signalingLearning and memoryCerebellar development
04

Disease associations

SchizophreniaEpilepsyNeurodevelopmental disorderCerebellar ataxiaBipolar disorder
05

Safety considerations

Psychotomimetic effectsCognitive impairmentMotor ataxiaDizzinessSedation
06

Interacting drugs

Memantine

4 more in the full profile.

07

Biomarkers

GRIN2C genetic variantsCerebellar volume (imaging)Glutamate levels in cerebrospinal fluid

Beyond the preview

Go deeper on Glutamate receptor ionotropic NMDA type subunit 2C (GRIN2C) (GRIN2C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor ionotropic NMDA type subunit 2C (GRIN2C) (GRIN2C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call